DALLAS, November 27, 2014 /PRNewswire/ --
ReportsnReports.com adds Rheumatoid Arthritis - Pipeline Review, H2 2014 market research report that provides comprehensive information on the therapeutic development for Rheumatoid Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis and special features on late-stage and discontinued projects. Complete report is available at http://www.reportsnreports.com/reports/318778-rheumatoid-arthritis-pipeline-review-h2-2014.html .
Rheumatoid Arthritis - Pipeline Review, H2 2014 report provides an overview of the Rheumatoid Arthritis's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Scope of the Rheumatoid Arthritis - Pipeline Review, H2 2014 report includes a snapshot of the global therapeutic landscape of Rheumatoid Arthritis, key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities as well as key players involved in the therapeutics development for Rheumatoid Arthritis and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects, provides a review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages and a detailed assessment of monotherapy and combination therapy pipeline projects is also provided in this research. Coverage of the Rheumatoid Arthritis pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products are covered in this research report.
Order a copy of Rheumatoid Arthritis - Pipeline Review, H2 2014 report at http://www.reportsnreports.com/Purchase.aspx?name=318778 . Reasons to buy this report include: it provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. Helps identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Develop strategic initiatives by understanding the focus areas of leading companies, identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics, develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope and modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Figures provided in Rheumatoid Arthritis - Pipeline Review, H2 2014 along with data tables include:
Number of Products under Development for Rheumatoid Arthritis, H2 2014 61
Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H2 2014 62
Number of Products under Development by Companies, H2 2014 63
Number of Products under Investigation by Universities/Institutes, H2 2014 83
Comparative Analysis by Late Stage Development, H2 2014 87
Comparative Analysis by Clinical Stage Development, H2 2014 88
Comparative Analysis by Early Stage Products, H2 2014 89
Assessment by Monotherapy Products, H2 2014 345
Assessment by Combination Products, H2 2014 346
Number of Products by Top 10 Targets, H2 2014 347
Number of Products by Stage and Top 10 Targets, H2 2014 347
Number of Products by Top 10 Mechanism of Actions, H2 2014 359
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 359
Number of Products by Top 10 Routes of Administration, H2 2014 370
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 370
Number of Products by Top 10 Molecule Types, H2 2014 372
Number of Products by Stage and Top 10 Molecule Types, H2 2014 372
Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts